You are here

Michael Mesleh

Michael Mesleh, Ph.D.

Michael Mesleh is a senior group leader of the biophysics team in the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard under the direction of Martin Drysdale. In collaboration with various groups, Mesleh is responsible for designing and leading fragment-based lead discovery and structure-based design projects. His research interests are in developing methodologies to address unmet challenges in drug discovery such as membrane proteins, biomolecular assemblies, dynamic proteins, protein-protein interfaces, and intact cells.

Prior to joining the Broad Institute in 2015, Mesleh started his career in structural chemistry at Neurocrine Biosciences and Arena Pharmaceuticals, where he contributed to several drug discovery and development programs focused on GPCRs. He later joined the Discovery Technologies group at Cubist Pharmaceuticals, where he was responsible for initiating Nuclear Magnetic Resonance (NMR)-based approaches to the discovery of new antibacterials (including fragment-based lead discovery and metabolomics) and co-led the exploratory research group. During his career he has utilized his expertise in NMR spectroscopy to identify, validate, and optimize ligands for various drug targets. He has also contributed to clinical programs for lorcaserin, nelotanserin, temanogrel, daptomycin, and surotomycin.

Mesleh holds a B.A. from the Integrated Science Program at Northwestern University, a M.Sc. in chemistry from the University of Pennsylvania, and a Ph.D. in biochemistry from University of California, San Diego. As an undergraduate he was awarded the Charles D. Hurd Scholarship and the Hypercube Scholarship in Theoretical Chemistry.

Contact Michael Mesleh via email at

August 2018